STOCK TITAN

Insight Molecular Diagnostics: Trust acquires 1.14M shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Insight Molecular Diagnostics Inc. (IMDX) reported that the Smith Irrevocable Trust acquired 1,142,857 shares of common stock on November 17, 2026, in the issuer’s underwritten public offering at $1.75 per share. The Trust directly held 4,401,342 shares after the transaction. Patrick W. Smith, a ten-percent owner, is the Trust’s trustee and may be deemed to beneficially own its securities. No Rule 10b5-1 plan is reported.

Insider SMITH PATRICK W
Role 10% Owner
Type Security Shares Price Value
Other Common Stock F1, F2 1,142,857 $1.75 $2.00M
Holdings After Transaction: Common Stock — 4,401,342 shares (Indirect, See Footnote)
Holdings Before and After: Common Stock, 3,258,485 to 4,401,342 shares (Indirect, See Footnote)
Footnotes (2)
  1. F1. Reflect shares of Insight Molecular Diagnostics Inc.'s (the "Issuer") common stock, no par value, purchased by the Reporting Person in an underwritten public offering of the Issuer at the public offering price of $1.75.
  2. F2. The shares of common stock reported herein are directly held by Patrick W Smith The Smith Irrevocable Trust U/A DTD 05/01/2015 (the "Trust"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust.
Shares acquired by the Trust 1,142,857 shares November 17, 2026 transaction
Public offering price $1.75 per share Price for the acquired shares
Trust shares after transaction 4,401,342 shares Reported position following the transaction
underwritten public offering financial
"in an underwritten public offering of the Issuer"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
beneficially own regulatory
"may be deemed to beneficially own the securities held by the Trust"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IMDX shares did the Smith Irrevocable Trust acquire, and at what price?

1,142,857 shares at $1.75 per share were acquired by the Smith Irrevocable Trust on November 17, 2026, in Insight Molecular Diagnostics Inc.’s underwritten public offering. The Trust directly held 4,401,342 shares after the transaction. Patrick W. Smith, a ten-percent owner, is its trustee and may be deemed to beneficially own the shares. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SMITH PATRICK W

(Last)(First)(Middle)
C/O INSIGHT MOLECULAR DIAGNOSTICS INC.
2 INTERNATIONAL PLAZA, SUITE 510

(Street)
NASHVILLE TENNESSEE 37217

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Insight Molecular Diagnostics Inc. [ IMDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026J1,142,857(1)A$1.754,401,342ISee Footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflect shares of Insight Molecular Diagnostics Inc.'s (the "Issuer") common stock, no par value, purchased by the Reporting Person in an underwritten public offering of the Issuer at the public offering price of $1.75.
2. The shares of common stock reported herein are directly held by Patrick W Smith The Smith Irrevocable Trust U/A DTD 05/01/2015 (the "Trust"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust.
/s/ Patrick W. Smith11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading